CASE CCC IN THE NEWS
Head and Neck Cancers: New Research Delves Deeper into Quality-of-Life Concerns
Oncology Times - May 25, 2014 Issue
Quality-of-life (QOL) concerns were front and center in the research reported at the Multidisciplinary Head and Neck Cancer Symposium. That common theme, noted Case Comprehensive Cancer Center member Mitchell Machtay, MD, Chairman of the Department of Radiation Oncology at University Hospitals Case Medical Center, the moderator of a news conference during the meeting, "shows the increased importance that we as physicians and the cancer care team are placing on quality of life, patient-reported outcomes, and [what is sometimes a] disconnect between how physicians and patients themselves assess side effects."
European Urology Published Groundbreaking Results from Three Studies Demonstrating Genomic Health's Oncotype DX® Test Predicts Prostate Cancer Aggressiveness at Diagnosis
Market Watch - May 16, 2014
Genomic Health, Inc. announced today that groundbreaking results from three studies of the Oncotype DX® prostate cancer test were published in European Urology. Developed and validated in collaboration with Cleveland Clinic and University of California, San Francisco (UCSF), the Oncotype DX prostate cancer test addresses the unique challenges of local prostate cancer diagnosis and treatment by revealing the underlying biology of the tumor and using genes from multiple biologic pathways to predict the aggressiveness of prostate cancer when diagnosed. "Our extensive development studies addressed the key challenges inherent to prostate cancer and helped overcome tumor heterogeneity and biopsy under-sampling and under-staging to develop a prostate cancer test that improves risk assessment at the time of diagnosis," said Eric A. Klein, MD, chairman, Glickman Urological and Kidney Institute, Cleveland Clinic, member of the Case Comprehensive Cancer Center, and principal investigator for the Cleveland Clinic's original development studies.
University Hospitals Case Medical Center Experts to Present Data at the 50th ASCO Annual Meeting Highlighting New Way to Predict Response to Chemotherapy For Triple-Negative Breast Cancer Patients
Yahoo Finance - May 14, 2014
Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer. The data are being presented at the 50th American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago. "Triple-negative breast cancers tend to be more aggressive compared to other types of breast cancers, and being able to predict response to therapy could greatly impact treatment decisions and patient outcomes," says study author Shaveta Vinayak, MD, oncologist at UH Case Medical Center, Assistant Professor at Case Western Reserve University School of Medicine, and member of the Case Comprehensive Cancer Center.
Germline PTEN Mutations Raise Second-Cancer Risk
Medscape - May 13, 2014
Individuals with germline PTEN mutations who have PTEN hamartoma tumor syndrome (PHTS) are known to be at increased risk for cancer, but a new study shows that the increased risk holds not only for first cancer, but for secondary malignancies as well. In the study, almost half of cancer patients who had germline pathogenic mutations in PTEN developed second malignant neoplasms (mostly breast, thyroid, and endometrial cancers), and having the mutation raised the lifetime risk for breast cancer to 85%, report senior author Charis Eng, MD, PhD, FACP, director of the Center for Personalized Genetic Healthcare at the Cleveland Clinic, and colleagues.
A Breathalyzer That Can Diagnose Cancer
The Atlantic - May 13, 2014
If a fingerprint can tell someone who you are, a "breathprint" could reveal how you're doing. That's according to Raed Dweik, the doctor who runs the pulmonary vascular program at the Cleveland Clinic's Respiratory Institute. For the past two decades, Dweik has been studying the molecular patterns in breath that can reveal what's happening inside the body. In the same way that a pocket of air above the water level in a closed container carries signature molecules that reflect the composition of that water, our breath is directly linked to what's happening in our blood. "A lot of people just think breath is what's in your lungs," Dweik told me. "We realize now that anything in your body that is eventually in the blood can be measured in your breath."
Red Wine and Health: Resveratrol Health Benefits a Myth?
MedPage Today - May 12, 2014
Resveratrol – an antioxidant found in red wine, chocolate, and grapes – didn't correlate with longevity or lower risk of cancer or cardiovascular disease when dietary intake was directly measured in a prospective study...However, Nate Berger, MD, an oncologist at University Hospitals Case Medical Center and member of the Case Comprehensive Cancer Center, noted that there was no significant evidence of harm in the study to argue against higher resveratrol doses. "The study is absolutely not definitive," he argued. "Maybe you need to start having higher levels of resveratrol when you're 50 or 40 to have a benefit."
Treating Multiple Myeloma: The Cause for Optimism
Journal of the National Cancer Institute - May 9, 2014
Frederic Reu, MD, associate staff physician at the Cleveland Clinic and member of the Case Comprehensive Cancer Center, noted that "in the current age of novel drugs, it is not clear whether stem cell transplant still prolongs life, although it remains one effective way to extend disease control. For patients who are started on lenalidomide, continued treatment at lower maintenance doses until disease progression appears to yield an improvement in life expectancy, however."
Before You Begin Cancer Treatment
Web MD - May 2014
There's no preparing for a cancer diagnosis. But when it comes to cancer treatment, there are things you can do to get ready for what's ahead. Experts say even taking small steps can improve your sense of well-being and control. Here are some things to do before your chemotherapy or radiation treatment begins. "One of the single most important things you can do is to make sure you and your cancer care team are on the same page about exactly what your treatment entails," says Dale R. Shepard, MD, PhD, of the Cleveland Clinic and Case Comprehensive Cancer Center. "That includes what will happen during treatment, how long treatment will take, what the potential side effects are, and what the ultimate goal of your treatment is."
RESEARCH HIGHLIGHTS/MEMBER NEWS
Dr. Sanjay Gupta Receives Award for Outstanding Contributions to Cancer Research
Dr. Sanjay Gupta was one of seven doctors recognized recently by the Society of Asian American Scientists in Cancer Research for outstanding contributions to cancer research. Dr. Gupta is the Carter Kissell Associate Professor and Research Director in the Department of Urology at CWRU and UHCMC. He is also a member of the Case Comprehensive Cancer Center
Dr. Eric A. Klein Honored by American Urological Society
Each year, the American Urological Association (AUA) honors the contributions of physician researchers and educators to the field of medicine, the specialty of urology, and the AUA. Eric A. Klein, MD, Chairman, Glickman Urological and Kidney Institute and Case Comprehensive Cancer Center member, is the recipient of the 2014 Presidential Citation for his work in innovative research in molecular markers in prostate cancer, leadership of Society for Urologic Oncology and building a center of excellence at Cleveland Clinic. The award will be presented on Tuesday, May 20 at the AUA Annual Meeting in Orlando, Florida.
Madabhushi Team Awarded Patent in Digital Pathology and Cancer Detection
Dr. Anant Madabhushi, Associate Professor, Biomedical Engineering and member of the Case Comprehensive Cancer Center, has been awarded a US patent 8718340, titled System and method for accurate and rapid identification of diseased regions on biological images with applications to disease diagnosis and prognosis. The invention relates to a method and system for detecting biologically relevant structures in a hierarchical fashion, beginning at a low-resolution and proceeding to higher levels of resolution. Co-inventors include Dr. James Monaco (scientist, VuComp), Michael Feldman (University of Pennsylvania), John Tomaszewski (SUNY Buffalo) and CWRU BME research Associate Dr. Ajay Basavanhally.
OCTC and Oncology Working Group
On April 22, 2014, the Ohio Clinical Trials Collaborative (OCTC) – a group of nearly 70 clinicians, researchers, clinical trials coordinators, and compliance officers from eight medical centers and universities affiliated with the three Ohio Clinical and Translational Science Awards (CTSA) – met for the second time during its semi-annual working meeting in Columbus.
The OCTC is a new statewide initiative under the umbrella of Ohio Governor John Kasich's Medical Corridor project launched with the goals of creating jobs, attracting investors, improving health, and advancing medical science in Ohio. The OCTC is comprised of Ohio's three CTSA institutions and partners, and aims to utilize a reliant IRB mechanism, economies of scale, unique capacity, and existing statewide expertise to establish a robust clinical trials structure across Ohio. The OCTC is led by CWRU School of Medicine Dean Pamela Davis, MD, PhD, where James Chmiel, MD serves as the Director and Chief Executive.
As one of six OCTC working groups, the Oncology working group, led by Drs. Jill Barnholtz-Sloan and David Peereboom, has set its initial focus on neuro-oncology, and is made up of neuro-oncologists, neurosurgeons, radiation oncologists and translational researchers from four Ohio academic medical centers. In addition to Drs. Barnholtz-Sloan and Peereboom, Drs. Gene Barnett and Manmeet Ahluwalia (Cleveland Clinic), Lisa Rogers and Simon Lo (UHCMC), and Richard Curry (University of Cincinnati Medical Center) attended the all-day event and the Oncology working group meeting. Other physicians involved with the group are Drs. Andrew Sloan (UHCMC), Ronald Warnick and Christopher McPherson (University of Cincinnati Medical Center) and Vinay Puduvalli and J Bradley Elder (Ohio State University Medical Center). The group discussed the current state of their prioritized multi-site therapeutic studies, ideas for new studies and expansion to pediatric neuro-oncology. For more information about the OCTC, visit http://casemed.case.edu/ctsc/octc/ or contact Dr. Jill Barnholtz-Sloan (firstname.lastname@example.org).
Lasker Clinical Research Scholars Program
NIH, in partnership with the Lasker Foundation, announced that it is accepting applications for the 2014-2015 Lasker Clinical Research Scholars Program to support early-stage, independent clinical researchers. The program, the first of its kind, combines a period of independent research in the NIH Intramural Research Program for five to seven years, with the opportunity for additional years of independent financial support either at the NIH or at an extramural research institution. Lasker Scholars will have access to the NIH Clinical Center, the nation's largest hospital devoted entirely to clinical research. Through an arrangement with the Lasker Foundation, Scholars will have the opportunity to participate in selected activities, including attendance at the Lasker Breakfast and Award Luncheon, and participation in annual scientific meetings.
Request for Letter of Support Deadline: June 2
Full Application Deadline: July 29
Limited Submission: Edward Mallinckrodt, Jr. Foundation
The Edward Mallinckrodt, Jr. Foundation is a private foundation that funds basic biomedical research in St Louis and throughout the United States. The mission of the Foundation is to support early stage investigators engaged in biomedical research that has the potential to significantly advance the understanding, diagnosis, or treatment of disease. The funds are designed to provide faculty members who hold MD and/or PhD degrees, and who are in the first to fourth year of a tenure-track position, with support to move the project forward to the point where R01 or other independent funding can be obtained. Applicants with current R01 funding should not apply.
Internal Deadline: June 16
External Deadline: August 1
BETRNet Pilot Projects
All Faculty members at participating institutions are invited to submit applications for Individual and/or Cross Barrett's Esophagus Translational Research Network (BETRNet) pilot projects of up to $50,000 to be funded by the U54 BETRNet. Note that a BETRNet project must be directed toward translational research related to Barrett's Esophagus. At least one specific aim should involve either direct patient contact or the study of patient derived tissue samples.
Deadline: June 6
Limited Submission: Pew Charitable Trusts: Pew Scholars Program in the Biomedical Sciences
The Pew Scholars Program in the Biomedical Sciencesprovides funding to young investigators of outstanding promise in science relevant to the advancement of human health. The program makes grants to selected academic institutions to support the independent research of outstanding individuals who are in their first few years of their appointment at the assistant professor level.
Internal Deadline: June 16
External Deadline: November 3
American Cancer Society Clinical Research Professor
The American Cancer Society offers a limited number of grants to mid-career investigators who have made seminal contributions in the area of cancer control that have changed the direction of clinical, psychosocial, behavioral, health policy or epidemiologic cancer research. Furthermore, it is expected that these investigators will continue to provide leadership in their research area. Up to two awards are made annually for a five-year term that can be renewed once. The award of up to $80,000 per year (direct costs only) may be used for salary or research project support. Interested individuals should submit their curriculum vitae with a complete bibliography and a letter of intent that briefly describes their seminal contributions to research.
LOI Deadline: August 1
Application Deadline: October 15
Damon Runyon Cancer Research Foundation
The Damon Runyon Cancer Research Foundation is accepting applications for the following opportunities:
- The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.
Deadline: July 1
- Fellowship Awards: The Foundation encourages all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies and prevention. Candidates must apply for the fellowship under the guidance of a Sponsor –a scientist (tenured, tenure-track or equivalent position) capable of providing mentorship to the Fellow. In addition to aiding in the planning, execution and supervision of the proposed research, the Sponsor's role is to foster the development of the Fellow's overall knowledge, technical and analytical skills, and capacity for scientific inquiry. The Sponsor is also expected to assist the Fellow in attaining his/her career goals. Candidates who have already accepted a postdoctoral research fellowship award are not eligible. Only one fellowship application will be accepted from a Sponsor (mentor) or Fellow per review session; there is no limit, however, to the number of applications from an institution.
Deadline: August 15
Harrington Prize for Innovation in Medicine
Nominations are being accepted for the Harrington Prize, presented by the American Society for Clinical Investigation and the Harrington Discovery Institute at University Hospitals Case Medical Center. This prize honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and potential for clinical application. Applicants must hold an MD or equivalent degree. Self-nomination is not permitted.
Deadline: August 15
Uniting Against Lung Cancer
Uniting Against Lung Cancer announces funding opportunities for research aimed at increasing survival for patients with lung cancers. The Foundation is prioritizing novel ideas with potential to make a significant impact on current treatment of lung cancer and patient survival. We have placed high priority on funding research that has a clear path to clinical application and/or therapeutic development. Proposals for basic science are greatly aided by a forward-looking research plan outlining clinical potential. UALC funding is intended primarily as seed money for promising and potentially transformative new projects, rather than funding projects that already receive considerable support. Cross discipline collaborations are strongly encouraged. Proposals do not require large amounts of preliminary data, but must have a clear hypothesis and research plan to be completed within the two year grant term.
Deadline: August 13
Join Our Team - Race for the Place
Walk or run with the Case Comprehensive Cancer Center team at the Race for the Place, June 1, 2014. This great event helps The Gathering Place to offer services to anyone touched by cancer, no matter their economic situation. Anyone is welcome to join our team. If you can't make the Race in person, please consider making a donation to support our efforts. Click here to view our team page.
MARK YOUR CALENDARS
Case CCC Clinical Research Retreat
The 2014 Case CCC Clinical Research Retreat will take place Tuesday, October 7, from 5-7 pm in the Wolstein Research Building Auditorium. The Retreat theme will be Immunotherapy. Please contact Dr. Smitha Krishnamurthi (smitha.krishnamurthi@UHhospitals.org) with any questions.
CME Event - Screening for Cancer in Women: 2014
Last chance to register for Screening for Cancer in Women: 2014, this Wednesday, May 21 at the Embassy Suites Hotel in Independence.
This conference will feature speakers from health centers across Northeast Ohio working together to fight cancer, who will offer expert insight, updates, and advice on screening for cancer in women.
KEYNOTE ADDRESS: Cancer Screening and Prevention in High-Risk Women
Allison Kurian, MD, MSc, Assistant Professor, Medicine (Oncology) and Health Research & Policy, Associate Director, Stanford Program in Clinical Cancer Genetics, Physician Leader, Stanford Women's Cancer Genetics Clinic, Stanford University
PRESENTERS AND PANELISTS
Stan Gerson, MD: Welcome
Holly Marshall, MD: Breast Cancer Screening
Jeff Marks, MD: Update on Colon Cancer Screening in Women
Brian Bolwell, MD: Affordable Care Act
Allison Vidimos, MD: Skin Cancer Screening in Women
Phyllis Nsiah-Kumi, MD, MPH: Cancer Disparities
Allison Kurian, MD, MSc; Donna Plecha, MD; Andrea Sikon, MD, FACP; Shaveta Vinayak, MD; Cindy Zelis, MD: Panel Discussion
Charles Lau, MD, MBA: Lung Screening
Kim Gecsi, MD: Gynecologic Cancer Screening
Paula Silverman, MD: Closing Remarks
CME credit will be offered. Visit the conference website for more details and registration information.
Call for Abstracts: Case CCC Annual Scientific Retreat
The Annual Case CCC Scientific Retreat will be held July 10-11, 2014. We will kick-off the retreat in late afternoon on Thursday, July 10 at the Wolstein Research Building with a keynote presentation by Kevin Shannon, MD from UCSF, an expert in Myc and RAS in cancer. A cocktail reception with heavy hors d'oeuvres will follow, allowing you the chance to network with your colleagues. New this year, there will be discussion of new members and their research, including poster presentations during the reception.
The retreat will continue Friday, July 11 at Corporate College East. We have a full scientific line-up of talks from Cancer Center members. A mid-day breakout for each scientific program to discuss new initiatives, collaborations, and requests for Cancer Center support through research pilot project and core resources will be one of the highlights of the day.
Finally, we will once again have poster presentations by the next generation of cancer researchers. All trainees, fellows and students are encouraged to submit an abstract. Monetary prizes will be awarded.
Pre-registration to attend the retreat is required. The retreat is open to Cancer Center members, Core Facility Directors/Managers, and students, fellows or postdocs who present posters. See the retreat webpage for more information.
NCRM Cancer Stem Cell Conference
The first CWRU: National Center for Regenerative Medicine Cancer Stem Cell Conference will be held in Cleveland, August 17-20, 2014. This conference is guaranteed to have incredible research from a variety of backgrounds in the Cancer Stem Cell field, and will feature keynote speakers from over 25 different institutions from around the world.
Attendees are invited to submit abstracts of original investigation for consideration in the conference poster session and possible short talk podium presentations. Accepted abstracts will be published online on the conference website and the conference program. Abstract submission deadline is June 1.
In addition, the conference will offer Cancer Stem Cell Conference Abstract Awards that are sponsored by the CWRU School of Medicine Dean's Office. Six outstanding graduate students will be chosen to receive free registration to attend this conference and present their abstracts. This opportunity is open to all graduate students interested in attending this conference. Contact Lyn Haselton (email@example.com; 216.844.5375) for more information.
PREVIOUSLY ANNOUNCED OPPORTUNITIES
L'Oréal USA For Women in Science Fellowship Program
DoD Prostate Cancer Research Program PCRP Biomarker Development Award
NIH BULLETIN – Notices and Funding Opportunities
Notice of Clarification Regarding the Additional Educational Information Required for PA-14-150 "Ruth L. Kirschstein National Research Service Award (NSRA) Individual Predoctoral MD/PhD or Other Dual-Doctoral Degree Fellowship (F30)" (NOT-OD-14-090)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.